| Half-life | 4 hours |
| Tmax | 2 h |
| Bioavailability | 75 % (approx) |
| Protein Binding | 30 % |
| Volume of Distribution | 0.6 L/kg (approx) |
| Clearance Route | renal |
| Active Metabolites | no |
| Notes | Reduce dose in CKD; baseline and periodic visual testing recommended. |
Severity: Severe
Adverse Effects:
Optic neuritis (↓visual acuity, red-green dyschromatopsia), rash
Contraindications:
Optic neuritis (active)
Precautions:
Baseline visual acuity & color vision; monitor monthly if high dose/long use